Yahoo
ASX - Delayed Quote AUD

Lumos Diagnostics Holdings Limited (LDX.AX)

0.0600 0.0000 (0.00%)
At close: November 6 at 4:10:28 PM GMT+11
Chart Range Bar
Loading chart for LDX.AX
  • Previous Close 0.0600
  • Open 0.0630
  • Bid 0.0600 x --
  • Ask 0.0630 x --
  • Day's Range 0.0600 - 0.0630
  • 52 Week Range 0.0550 - 0.3300
  • Volume 48,653
  • Avg. Volume 1,255,224
  • Market Cap (intraday) 59.29M
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 0.28
  • Moby Rating Neutral

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

lumosdiagnostics.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

LDX.AX
78.95%
S&P/ASX 200 [XJO] (^AXJO)
3.52%

1-Year Return

LDX.AX
65.71%
S&P/ASX 200 [XJO] (^AXJO)
2.86%

3-Year Return

LDX.AX
21.05%
S&P/ASX 200 [XJO] (^AXJO)
29.29%

5-Year Return

LDX.AX
92.21%
S&P/ASX 200 [XJO] (^AXJO)
20.97%

Analyst Insights

View More

Analyst Price Targets

0.20
0.28 Average
0.0600 Current
0.35 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.54%

  • Return on Assets (ttm)

    -28.69%

  • Return on Equity (ttm)

    -34.13%

  • Revenue (ttm)

    13.19M

  • Net Income Avi to Common (ttm)

    -4.95M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.43M

  • Total Debt/Equity (mrq)

    25.98%

  • Levered Free Cash Flow (ttm)

    -1.84M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: